Cardiomyopathy Trial, Recruiting (NCT07293338)

Cardiomyopathy Trial, Recruiting NCT07293338 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT07293338 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with dilated cardiomyopathy (an enlarged heart) confirmed by an ultrasound of the heart, where the heart's main pumping chamber measures more than 55 mm in men or more than 50 mm in women.
People who have signs and symptoms of heart failure, along with a specific blood marker result (BNP at 35 or above, or NT-proBNP at 125 or above), and a weakened heart pumping function where the heart pumps out less than 45% of its blood with each beat.
People whose heart artery imaging (a procedure that looks at the blood vessels of the heart) shows no significant blockages — meaning all major heart arteries have less than 50% narrowing.

Who may not be able to join:

People whose heart condition is caused by blocked heart arteries, high blood pressure affecting the heart, rheumatic valve disease, inflammation of the heart muscle, or any other known underlying cause of heart muscle disease.
People whose heart artery imaging results were not clear enough to assess properly.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86 15657125311

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07293338

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase: Not Applicable

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: +86 15657125311

More information: https://clinicaltrials.gov/study/NCT07293338

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with dilated cardiomyopathy (an enlarged heart) confirmed by an ultrasound of the heart, where the heart's main pumping chamber measures more than 55 mm in men or more than 50 mm in women.
People who have signs and symptoms of heart failure, along with a specific blood marker result (BNP at 35 or above, or NT-proBNP at 125 or above), and a weakened heart pumping function where the heart pumps out less than 45% of its blood with each beat.
People whose heart artery imaging (a procedure that looks at the blood vessels of the heart) shows no significant blockages — meaning all major heart arteries have less than 50% narrowing.

Who may not be able to join:

People whose heart condition is caused by blocked heart arteries, high blood pressure affecting the heart, rheumatic valve disease, inflammation of the heart muscle, or any other known underlying cause of heart muscle disease.
People whose heart artery imaging results were not clear enough to assess properly.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Registry

ClinicalTrials.gov

Start date

6 January 2026

Est. completion

1 November 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Major adverse cardiac events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov